SL
HRMY icon

Salomon & Ludwin’s Harmony Biosciences HRMY Stock Holding History

Salomon & Ludwin’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5K Buy
486
+316
+186% +$9.97K ﹤0.01% 1250
2026
Q1 		$4.72K Sell
170
-70
-29% -$2.29K ﹤0.01% 1777
2025
Q4 		$8.82K Buy
240
+152
+173% +$5K ﹤0.01% 1514
2025
Q3 		$2.4K Buy
+88
New +$3.03K ﹤0.01% 1950

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Salomon & Ludwin's HRMY Position: Q2 2026 in Review

Salomon & Ludwin increased its Harmony Biosciences (HRMY) stake by 186% in Q2 2026, buying an estimated $9.97K and bringing the position to 486 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1250.

Salomon & Ludwin first reported a position in HRMY in Q3 2025 and has held it in 4 quarters since. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Salomon & Ludwin held 486 shares of Harmony Biosciences worth $17.5K as of Q2 2026.
  • Salomon & Ludwin bought 316 Harmony Biosciences shares in Q2 2026, an estimated $9.97K.
  • Harmony Biosciences made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1250 holding.
  • Salomon & Ludwin first reported a position in Harmony Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.